{"id":2810,"date":"2026-08-24T22:27:12","date_gmt":"2026-08-24T22:27:12","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=2810"},"modified":"2026-08-24T22:27:13","modified_gmt":"2026-08-24T22:27:13","slug":"buy-cjc-1295-ghrp-2-blend-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-cjc-1295-ghrp-2-blend-in-switzerland\/","title":{"rendered":"CJC-1295 & GHRP-2 Blend (10MG)"},"content":{"rendered":"

What Is the CJC-1295 & GHRP-2 Blend and Why Buy It for Research?<\/strong><\/h2>\n

Buy CJC-1295 & GHRP-2 Blend in Switzerland for research into growth hormone axis signaling, synergistic GH release, and metabolic regulation. Specifically, this 10mg research formulation combines two complementary growth hormone secretagogues in a single pre-mixed lyophilized vial: CJC-1295 (Mod GRF 1-29, 5mg) and GHRP-2 (5mg). This blend pairs a growth hormone-releasing hormone (GHRH) analog with a potent growth hormone secretagogue (GHS) to probe convergent pathways in the GH-IGF-1 axis.<\/p>\n

CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic 29-amino acid peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. GHRP-2 (Pralmorelin, KP-102) is a synthetic hexapeptide that engages the GHS-R1a receptor, mobilizing intracellular calcium to trigger GH granule release. When combined, these two peptides produce synergistic GH release significantly higher than either compound alone. Furthermore, Core Peptides supplies this blend as a lyophilized powder in a 10mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy CJC-1295 & GHRP-2 Blend in Switzerland.<\/p>\n

CJC-1295 & GHRP-2 Blend Research Overview: Buy CJC-1295 & GHRP-2 Blend in Switzerland for GH Axis Studies<\/strong><\/h2>\n

Centrally, research into the CJC-1295 and GHRP-2 blend has focused on the complementary and synergistic mechanisms of its two components. The foundational observation that GHRH + GHRP produces synergistic GH release was established by Bowers et al. in human subjects, demonstrating that co-administration of GHRH and GHRP produced GH peaks significantly higher than either peptide alone.<\/p>\n

CJC-1295 (Mod GRF 1-29) functions as a GHRH analog that binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor (GPCR) on pituitary somatotrophs. The peptide incorporates four strategic amino acid substitutions at positions 2 (Ala to D-Ala), 8 (Asn to Gln), 15 (Gly to Ala), and 27 (Met to Leu), which confer resistance to DPP-IV cleavage and other degradation pathways, extending the biological half-life to approximately 30 minutes. The D-Ala substitution at position 2 is the most critical modification, as native GHRH is rapidly inactivated by DPP-IV, which cleaves the Tyr1-Ala2 peptide bond. This single modification extends the biological half-life from less than 7 minutes (native GHRH) to approximately 30 minutes.<\/p>\n

GHRP-2 (Pralmorelin, KP-102) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH\u2082. It acts directly on specific pituitary receptors and indirectly on the hypothalamus, stimulating endogenous GHRH release from arcuate nucleus neurons and functionally suppressing somatostatin release from periventricular neurons. This dual hypothalamic action creates a permissive environment for maximal GH pulse amplitude. GHRP-2 has a molecular weight of 817.9 Da and the molecular formula C\u2084\u2085H\u2085\u2085N\u2089O\u2086.<\/p>\n

When combined, CJC-1295 sustains physiologic pulsatile GH secretion while GHRP-2 amplifies output through hypothalamic effects and suppression of somatostatin. The dual-receptor activation model produces GH output that exceeds the additive sum of either peptide alone by two to three times. Accordingly, researchers who buy CJC-1295 & GHRP-2 Blend in Switzerland from Core Peptides can support their investigations into GH axis signaling, synergistic peptide interactions, and metabolic regulation.<\/p>\n

How Does the CJC-1295 & GHRP-2 Blend Work in Research?<\/strong><\/h2>\n

Mechanistically, the CJC-1295 and GHRP-2 blend operates through two complementary signaling pathways that converge on GH release from pituitary somatotrophs.<\/p>\n

GHRH Receptor Pathway (CJC-1295)<\/strong><\/h3>\n

CJC-1295 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. It functions as a stable and active hGRF1-29 analog with a half-life of approximately 30 minutes. This binding initiates a downstream signaling cascade that results in GH synthesis and release, with CJC-1295 showing a 4-fold increase in GH area under the curve over a 2-hour period compared with hGRF1-29. The form without DAC (Mod GRF 1-29) has a shorter half-life of approximately 30 minutes and mimics the natural, pulsatile release of GHRH.<\/p>\n

GHS-R1a Pathway (GHRP-2)<\/strong><\/h3>\n

GHRP-2 binds the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor, through Gq\/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. GHRP-2 is a potent agonist of GHS-R1a and has been shown to have GH-releasing activity greater than that of GHRH both in animals and in man. Beyond somatotroph GH release, GHRP-2 activates hypothalamic circuits that suppress somatostatin release and stimulate endogenous GHRH secretion, creating a feed-forward loop that further amplifies GH output.<\/p>\n

Synergistic Effects<\/strong><\/h3>\n

The dual combination produces synergistic (not merely additive) GH release. CJC-1295 sustains physiologic pulsatile GH secretion while GHRP-2 amplifies output through hypothalamic effects and suppression of somatostatin. Combining a GHS (GHRP-2) with a GHRH analog (CJC-1295) produces synergistic GH release significantly higher than either compound alone. Studies suggest that this blend may offer new insights into how fluctuations in growth hormone levels might impact overall energy balance and metabolic function.<\/p>\n

Why Is the CJC-1295 & GHRP-2 Blend Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study this blend because it represents a well-characterized dual combination of complementary GH secretagogues that enables investigation of synergistic GH release, metabolic regulation, and receptor pharmacology. In fact, this pre-mixed blend offers a practical way to study convergent GH axis signaling without the need to source and reconstitute each compound separately.<\/p>\n

Research has demonstrated the blend’s relevance across multiple domains. GH pulse amplitude is a key determinant of recovery-relevant downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity, supporting the value of high-amplitude pulse protocols. Furthermore, GHRP-2’s broader hypothalamic effects including somatostatin suppression and endogenous GHRH stimulation provide additional mechanisms for amplifying GH output. Ultimately, researchers who buy CJC-1295 & GHRP-2 Blend in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, metabolic regulation, and receptor pharmacology.<\/p>\n

CJC-1295 & GHRP-2 Blend Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nKey Components<\/th>\n<\/tr>\n<\/thead>\n
GH Axis Signaling<\/td>\nDual-pathway activation, GHRH\/GHS receptor crosstalk, pulsatile secretion<\/td>\nBoth (complementary pathways)<\/td>\n<\/tr>\n
Metabolic Regulation<\/td>\nIGF-1 elevation, lipolysis, protein synthesis, metabolic homeostasis<\/td>\nBoth (GH-dependent effects)<\/td>\n<\/tr>\n
Receptor Pharmacology<\/td>\nGHRH-R, GHS-R1a binding, receptor binding kinetics, dual-receptor activation<\/td>\nBoth (distinct targets)<\/td>\n<\/tr>\n
Hypothalamic-Pituitary Axis<\/td>\nSomatostatin suppression, endogenous GHRH release, feed-forward amplification<\/td>\nGHRP-2<\/td>\n<\/tr>\n
Pulsatile GH Secretion<\/td>\nPhysiologic GH patterning, amplitude modulation, pulse dynamics<\/td>\nCJC-1295<\/td>\n<\/tr>\n
Energy Balance Research<\/td>\nMetabolic function, energy homeostasis, growth hormone fluctuations<\/td>\nBoth<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CJC-1295 & GHRP-2 Blend Compared With Related Research Formulations<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Formulation<\/th>\nComponents<\/th>\nResearch Focus<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
CJC-1295 + GHRP-2 Blend<\/td>\nCJC-1295 (Mod GRF 1-29) + GHRP-2 (1:1)<\/td>\nGH axis, synergistic release, metabolic regulation<\/td>\nClassic GH stack; broad hypothalamic effects via GHRP-2<\/td>\n<\/tr>\n
CJC-1295 + Ipamorelin Blend<\/td>\nCJC-1295 + Ipamorelin<\/td>\nGH release, metabolic regulation<\/td>\nWeaker GH pulse; minimal cortisol\/prolactin spillover<\/td>\n<\/tr>\n
CJC-1295 + Hexarelin Blend<\/td>\nCJC-1295 + Hexarelin<\/td>\nGH axis, cardioprotection<\/td>\nHexarelin adds CD36 cardioprotection<\/td>\n<\/tr>\n
CJC-1295 + Ipamorelin + GHRP-2 Blend<\/td>\nCJC-1295 + Ipamorelin + GHRP-2 (1:1:1)<\/td>\nTriple-pathway GH axis, receptor pharmacology<\/td>\nTriple blend; dual GHS-R1a agonism<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, the CJC-1295 and GHRP-2 blend differs from other GHRH\/GHS combinations in its potency and hypothalamic effects. On the one hand, GHRP-2 is one of the most potent GHRPs, generating robust GH output alongside measurable increases in ACTH, cortisol, and prolactin. On the other hand, the CJC-1295 and Ipamorelin blend provides selective GH release with minimal cortisol elevation. In contrast, the CJC-1295 and Hexarelin blend adds CD36-mediated cardioprotection, while the triple blend (CJC-1295 + Ipamorelin + GHRP-2) adds a second GHS-R1a agonist for more complete receptor activation.<\/p>\n

Research Applications for the CJC-1295 & GHRP-2 Blend in Switzerland<\/strong><\/h2>\n

Scientists have investigated this peptide blend across several research domains:<\/p>\n